查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1264002

多發性骨髓瘤市場:規模，全球市場的預測(2023年～2030年)，產業趨勢，成長，佔有率，預測，通貨膨脹的影響，企業的機會分析

Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis
出版日期: | 出版商: Renub Research | 英文 350 Pages | 商品交期: 最快1-2個工作天內

價格

全球多發性骨髓瘤的市場規模在2022年估算為102億美金，2030年將達到163億1,000萬美元。2022年～2030年預計將以年複合成長率6.04％的速度成長。

本報告提供全球多發性骨髓瘤市場相關調查，提供疾病概要，以及流行病學·患者趨勢，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 促進因素
  • 課題
  • 機會

第5章 波特的五力分析

第6章 SWOT分析- 多發性骨髓瘤市場

第7章 全球多發性骨髓瘤(MM)- 市場與患者數

第8章 佔有率分析- 全球多發性骨髓瘤

  • 各國市場佔有率
  • 治療各類型市場佔有率
  • 流行病學情勢佔有率
  • 性別佔有率

第9章 多發性骨髓瘤- 疾病概要

  • 簡介
  • 症狀與診斷
  • 病理學
  • 原因和危險因素
  • 治療

第10章 多發性骨髓瘤的患者趨勢

第11章 多發性骨髓瘤- 流行病學和患者數

  • 市場流行病學情勢-主要10個國家
  • 流行病學情勢-美國
  • 流行病學情勢-德國
  • 流行病學情勢-法國
  • 流行病學情勢- 英國
  • 流行病學情勢-義大利
  • 流行病學情勢-西班牙
  • 流行病學情勢-日本
  • 流行病學情勢-澳洲
  • 流行病學情勢-中國
  • 流行病學情勢-沙烏地阿拉伯

第12章 多發性骨髓瘤- 流行病學和患者數- 性別

  • 市場流行病學情勢-主要10個國家
  • 流行病學情勢-美國
  • 流行病學情勢-德國
  • 流行病學情勢-法國
  • 流行病學情勢-英國
  • 流行病學情勢-義大利
  • 流行病學情勢-西班牙
  • 流行病學情勢-日本
  • 流行病學情勢-澳洲
  • 流行病學情勢-中國
  • 流行病學情勢-沙烏地阿拉伯

第13章 多發性骨髓瘤- 市場情勢

  • 市場情勢-重要的洞察
  • 市場市場情勢-主要10個國家
  • 市場情勢-美國
  • 市場情勢-德國
  • 市場情勢-法國
  • 市場情勢-英國
  • 市場情勢-義大利
  • 市場情勢-西班牙
  • 市場情勢-日本
  • 市場情勢-澳洲
  • 市場情勢-中國
  • 市場情勢-沙烏地阿拉伯

第14章 多發性骨髓瘤-治療流程，指南，及醫療行為

第15章 多發性骨髓瘤的未滿足需求

第16章 多發性骨髓瘤-治療重要的端點

  • 標靶治療
  • 化療
  • 其他

第17章 多發性骨髓瘤-已上市產品

第18章 多發性骨髓瘤-正在開發的藥物

第19章 企業分析

  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • AstraZeneca

Multiple Myeloma Market will reach US$ 16.31 Billion in 2030 compared to 10.20 Billion in 2022, according to Renub Research. Multiple myeloma, or Kahler's disease, is a cancer that impacts plasma cells, white blood cells that generate antibodies to combat infections. The condition results in an accumulation of abnormal plasma cells in the bone marrow, which produce an abnormal protein called monoclonal immunoglobulin (M protein) that may damage the bones and other organs.

According to the Globocan, there were an estimated 19,292,789 new cancer cases, resulting in approximately 9,958,133 cancer-related deaths. In addition, the International Agency for Research on Cancer (IARC) projects that the global cancer incidence will rise to 27.5 million new cases with 16.3 million deaths by 2040.

Multiple Myeloma testing markets shall experience a CAGR of 6.04% from 2022 to 2030

Multiple myeloma, the second most prevalent type of blood cancer after non-Hodgkin lymphoma, is identified by the uncontrolled growth of abnormal plasma cells within the bone marrow. The malignant plasma cells displace normal blood cells, causing low blood counts, bone deterioration, and possible kidney impairment. Recent advancements in drugs for multiple myeloma have revolutionized treatment in the last decade, and future agents in development offer promising breakthroughs.

An increase in early detection and diagnosis of multiple myeloma leads to earlier treatment and better patient outcomes. Moreover, advancing targeted therapies and immunotherapies have led to the development of newer and more effective treatments for multiple myeloma. Finally, increased awareness and advocacy efforts for multiple myeloma may lead to more research funding and greater attention to the condition, further driving growth in the industry.

Chemotherapy will be the most preferred type of Treatment in the Future

Targeted Therapy, Chemotherapy, and Others are the different treatment types used in the multiple myeloma industry. Chemotherapy is a critical component of multiple myeloma treatment and has contributed to the growth of the chemotherapy market in this field. It effectively kills dividing cancer cells, vital for controlling abnormal plasma cell proliferation. New chemotherapy drugs with improved efficacy and reduced toxicity have increased their use in treating multiple myeloma. Moreover, chemotherapy is often combined with other treatments, such as immunotherapy and targeted therapy, to improve outcomes. Therefore, the demand for chemotherapy treatments will grow as multiple myeloma prevalence increases.

Males are at a greater risk of developing the Disease

Both Male and Female genders are at risk of multiple myeloma. Males have higher levels of androgens that can promote the growth of abnormal plasma cells. Occupational exposure to certain chemicals and risky behaviors such as smoking and heavy alcohol consumption may also increase the risk of multiple myeloma in males. In addition, genetic mutations that increase the risk of multiple myeloma may also be more common in males.

Multiple myeloma is more prevalent in older adults, and since females generally have a longer lifespan than males, they are more susceptible to developing the disease. In addition, some research indicates that female hormones may contribute to developing multiple myeloma. For instance, estrogen may stimulate the proliferation of myeloma cells, elevating the risk of multiple myeloma in females.

United States has the highest Epidemiology Scenario Share

Based on the epidemiology scenario share, the report covers 10 top countries - United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia.The United States' large and diverse population, advanced healthcare system, and robust research infrastructure have contributed to its dominance in the multiple myeloma industry. In addition, the country's favorable regulatory environment for new cancer treatments and numerous patient advocacy organizations have also played a role in the industry's growth.

The UK's robust healthcare system and strong tradition of medical research in multiple myeloma led to a high concentration of healthcare professionals and researchers with expertise in the country, along with a favorable regulatory environment for developing and approving new treatments. Additionally, several organizations' dedication in the UK raises awareness and supports patients and their families, leading to greater attention and funding for research in the field.

China's Increasing Number of Aging Population have increased the incidence of Multiple Myeloma

The United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia are the countries that comprise the multiple myeloma market in this report. China's growing and aging population has led to a higher incidence of multiple myeloma and growth in the industry. Increased healthcare spending due to economic development has improved cancer care, including for multiple myeloma. China's diverse patient population presents opportunities for new treatments and clinical trials, while government policies support the biopharmaceutical industry. Renowned research institutions and collaborations with international pharmaceutical companies have contributed to the transfer of advanced technologies and growth in the industry.

Renub Research report titled "Multiple Myeloma Market Global Forecast by Countries (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia), Treatment Types (Targeted therapy, Chemotherapy, and Others), Epidemiology Scenario Share (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia), Gender share (Male, and Female)," provides a detailed analysis of Multiple Myeloma Market.

Countries - Market breakup from 10 Viewpoints:

1. United States

2. United Kingdom

3. Germany

4. France

5. Spain

6. Italy

7. Japan

8. Australia

9. China

10. Saudi Arabia

Treatment Types - Market breakup from 3 Viewpoints:

1. Targeted therapy

2. Chemotherapy

3. Others

Epidemiology Scenario Share - Market breakup from 10 Viewpoints:

1. United States

2. United Kingdom

3. Germany

4. France

5. Spain

6. Italy

7. Japan

8. Australia

9. China

10. Australia

Gender Share - Market breakup from 2 Viewpoints:

1. Male

2. Female

All companies have been covered from 3 viewpoints

  • Overviews
  • Recent Developments
  • Revenues

Company

1. Sanofi (France)

2. Pfizer Inc. (US)

3. GlaxoSmithKline plc (UK)

4. Novartis AG (Switzerland)

5. Bayer AG (Germany)

6. Eli Lilly and Company (US)

7. Merck & Co., Inc. (US)

8. AstraZeneca

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Porter's Five Forces

  • 5.1 Bargaining Power of Buyers
  • 5.2 Bargaining Power of Suppliers
  • 5.3 Degree of Competition
  • 5.4 Threat of New Entrants
  • 5.5 Threat of Substitutes

6 SWOT Analysis - Multiple Myeloma Market

  • 6.1 Strengths
  • 6.2 Weaknesses
  • 6.3 Opportunities
  • 6.4 Threats

7. Global Multiple Myeloma (MM) - Market & Patient Numbers

  • 7.1 Multiple Myeloma Market
  • 7.2 Multiple Myeloma Patient Population

8. Share Analysis - Global Multiple Myeloma

  • 8.1 By Countries Market Share
  • 8.2 By Treatment Types Market Share
  • 8.3 By Epidemiology Scenario Share
  • 8.4 By Gender Share

9. Multiple Myeloma - Disease Overview

  • 9.1 Introduction
  • 9.2 Symptoms and Diagnosis
  • 9.3 Pathophysiology
  • 9.4 Causes and Risk Factors
  • 9.5 Treatment

10. Multiple Myeloma Patient Journey

11. Multiple Myeloma - Epidemiology and Patient Population

  • 11.1 Epidemiology Scenario - Top 10 Markets
    • 11.1.1 Epidemiology Scenario (2017-2022)
    • 11.1.2 Epidemiology Forecast (2023-2030)
  • 11.2 Epidemiology Scenario - United States
    • 11.2.1 Epidemiology Scenario (2017-2022)
    • 11.2.2 Epidemiology Forecast (2023-2030)
  • 11.3 Epidemiology Scenario - Germany
    • 11.3.1 Epidemiology Scenario (2017-2022)
    • 11.3.2 Epidemiology Forecast (2023-2030)
  • 11.4 Epidemiology Scenario - France
    • 11.4.1 Epidemiology Scenario (2017-2022)
    • 11.4.2 Epidemiology Forecast (2023-2030)
  • 11.5 Epidemiology Scenario - United Kingdom
    • 11.5.1 Epidemiology Scenario (2017-2022)
    • 11.5.2 Epidemiology Forecast (2023-2030)
  • 11.6 Epidemiology Scenario - Italy
    • 11.6.1 Epidemiology Scenario (2017-2022)
    • 11.6.2 Epidemiology Forecast (2023-2030)
  • 11.7 Epidemiology Scenario - Spain
    • 11.7.1 Epidemiology Scenario (2017-2022)
    • 11.7.2 Epidemiology Forecast (2023-2030)
  • 11.8 Epidemiology Scenario - Japan
    • 11.8.1 Epidemiology Scenario (2017-2022)
    • 11.8.2 Epidemiology Forecast (2023-2030)
  • 11.9 Epidemiology Scenario - Australia
    • 11.11.1 Epidemiology Scenario (2017-2022)
    • 11.11.2 Epidemiology Forecast (2023-2030)
  • 11.10 Epidemiology Scenario - China
    • 11.10.1 Epidemiology Scenario (2017-2022)
    • 11.10.2 Epidemiology Forecast (2023-2030)
  • 11.11 Epidemiology Scenario - Saudi Arabia
    • 11.11.1 Epidemiology Scenario (2017-2022)
    • 11.11.2 Epidemiology Forecast (2023-2030)

12. Multiple Myeloma - Epidemiology and Patient Population - By Gender

  • 12.1 Epidemiology Scenario - Top 10 Markets
    • 12.1.1 Epidemiology Scenario Male and Forecast
    • 12.1.2 Epidemiology Scenario Female Forecast
  • 12.2 Epidemiology Scenario - United States
    • 12.2.1 Epidemiology Scenario Male and Forecast
    • 12.2.2 Epidemiology Scenario Female Forecast
  • 12.3 Epidemiology Scenario - Germany
    • 12.3.1 Epidemiology Scenario Male and Forecast
    • 12.3.2 Epidemiology Scenario Female Forecast
  • 12.4 Epidemiology Scenario - France
    • 12.4.1 Epidemiology Scenario Male and Forecast
    • 12.4.2 Epidemiology Scenario Female Forecast
  • 12.5 Epidemiology Scenario - United Kingdom
    • 12.5.1 Epidemiology Scenario Male and Forecast
    • 12.5.2 Epidemiology Scenario Female Forecast
  • 12.6 Epidemiology Scenario - Italy
    • 12.6.1 Epidemiology Scenario Male and Forecast
    • 12.6.2 Epidemiology Scenario Female Forecast
  • 12.7 Epidemiology Scenario - Spain
    • 12.7.1 Epidemiology Scenario Male and Forecast
    • 12.7.2 Epidemiology Scenario Female Forecast
  • 12.8 Epidemiology Scenario - Japan
    • 12.8.1 Epidemiology Scenario Male and Forecast
    • 12.8.2 Epidemiology Scenario Female Forecast
  • 12.9 Epidemiology Scenario - Australia
    • 12.9.1 Epidemiology Scenario Male and Forecast
    • 12.9.2 Epidemiology Scenario Female Forecast
  • 12.10 Epidemiology Scenario - China
    • 12.12.1 Epidemiology Scenario Male and Forecast
    • 12.12.2 Epidemiology Scenario Female Forecast
  • 12.11 Epidemiology Scenario - Saudi Arabia
    • 12.11.1 Epidemiology Scenario Male and Forecast
    • 12.11.2 Epidemiology Scenario Female Forecast

13. Multiple Myeloma - Market Scenario

  • 13.1 Market Scenario - Key Insights
  • 13.2 Market Scenario - Top 10 Markets
    • 13.2.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.2.2 Market Forecast (2023-2030)
  • 13.3 Market Scenario - United States
    • 13.3.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.3.2 Market Size Forecast (2023-2030)
    • 13.3.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.4 Market Scenario - Germany
    • 13.4.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.4.2 Market Size Forecast (2023-2030)
    • 13.4.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.5 Market Scenario - France
    • 13.5.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.5.2 Market Size Forecast (2023-2030)
    • 13.5.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.6 Market Scenario - United Kingdom
    • 13.6.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.6.2 Market Size Forecast (2023-2030)
    • 13.6.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.7 Market Scenario - Italy
    • 13.7.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.7.2 Market Size Forecast (2023-2030)
    • 13.7.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.8 Market Scenario - Spain
    • 13.8.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.8.2 Market Size Forecast (2023-2030)
    • 13.8.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.9 Market Scenario - Japan
    • 13.9.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.9.2 Market Size Forecast (2023-2030)
    • 13.9.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.10 Market Scenario - Australia
    • 13.10.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.10.2 Market Size Forecast (2023-2030)
    • 13.10.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.11 Market Scenario - China
    • 13.13.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.13.2 Market Size Forecast (2023-2030)
    • 13.13.3 Multiple Myeloma - Access and Reimbursement Overview
  • 13.12 Market Scenario - Saudi Arabia
    • 13.12.1 Multiple Myeloma - Market Size (2017-2022)
    • 13.12.2 Market Size Forecast (2023-2030)
    • 13.12.3 Multiple Myeloma - Access and Reimbursement Overview

14. Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices

  • 14.1 Guidelines, Management and Treatment
  • 14.2 Treatment Algorithm

15. Multiple Myeloma Unmet Needs

16. Multiple Myeloma - Key Endpoints of Treatment

  • 16.1 Targeted Therapy
  • 16.2 Chemotherapy
  • 16.3 Others

17. Multiple Myeloma - Marketed Products

  • 17.1 List of Multiple Myeloma Marketed Drugs across the Top 10 Markets
    • 17.1.1 Xpovio (Selinexor) - Karyopharm
      • 17.1.1.1 Drug Overview
      • 17.1.1.2 Mechanism of Action
      • 17.1.1.3 Regulatory Status
      • 17.1.1.4 Clinical Trial Results
      • 17.1.1.5 Sales Across Major Markets
    • 17.1.2 Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical
      • 17.1.2.1 Drug Overview
      • 17.1.2.2 Mechanism of Action
      • 17.1.2.3 Regulatory Status
      • 17.1.2.4 Clinical Trial Results
      • 17.1.2.5 Sales Across Major Markets
    • 17.1.3 Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan)
      • 17.1.3.1 Drug Overview
      • 17.1.3.2 Mechanism of Action
      • 17.1.3.3 Regulatory Status
      • 17.1.3.4 Clinical Trial Results
      • 17.1.3.5 Sales Across Major Markets
    • 17.1.4 HDAC inhibitor (Farydak) - Novartis
      • 17.1.4.1 Drug Overview
      • 17.1.4.2 Mechanism of Action
      • 17.1.4.3 Regulatory Status
      • 17.1.4.4 Clinical Trial Results
      • 17.1.4.5 Sales Across Major Markets
    • 17.1.5 Sarclisa (Isatuximab) - Sanofi
      • 17.1.5.1 Drug Overview
      • 17.1.5.2 Mechanism of Action
      • 17.1.5.3 Regulatory Status
      • 17.1.5.4 Clinical Trial Results
      • 17.1.5.5 Sales Across Major Markets

18. Multiple Myeloma - Pipeline Drugs

  • 18.1 List of Multiple Myeloma Pipeline Drugs across the Top 10 Markets
    • 18.1.1 Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
      • 18.1.1.1 Drug Overview
      • 18.1.1.2 Mechanism of Action
      • 18.1.1.3 Clinical Trial Results
      • 18.1.1.4 Safety and Efficacy
      • 18.1.1.5 Regulatory Status
    • 18.1.2 Elranatamab - Pfizer
      • 18.1.2.1 Drug Overview
      • 18.1.2.2 Mechanism of Action
      • 18.1.2.3 Clinical Trial Results
      • 18.1.2.4 Safety and Efficacy
      • 18.1.2.5 Regulatory Status
    • 18.1.3 Alnuctamab - Celgene, Bristol-Myers Squibb
      • 18.1.3.1 Drug Overview
      • 18.1.3.2 Mechanism of Action
      • 18.1.3.3 Clinical Trial Results
      • 18.1.3.4 Safety and Efficacy
      • 18.1.3.5 Regulatory Status
    • 18.1.4 CAR-T ddBCMA - Gilead Sciences
      • 18.1.4.1 Drug Overview
      • 18.1.4.2 Mechanism of Action
      • 18.1.4.3 Clinical Trial Results
      • 18.1.4.4 Safety and Efficacy
      • 18.1.4.5 Regulatory Status
    • 18.1.5 Masitinib - AB Science
      • 18.1.5.1 Drug Overview
      • 18.1.5.2 Mechanism of Action
      • 18.1.5.3 Clinical Trial Results
      • 18.1.5.4 Safety and Efficacy
      • 18.1.5.5 Regulatory Status
    • 18.1.6 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
      • 18.1.6.1 Drug Overview
      • 18.1.6.2 Mechanism of Action
      • 18.1.6.3 Clinical Trial Results
      • 18.1.6.4 Safety and Efficacy
      • 18.1.6.5 Regulatory Status

19. Company Analysis

  • 19.1 Sanofi (France)
    • 19.1.1 Overview
    • 19.1.2 Recent Developments
    • 19.1.3 Financial Analysis
  • 19.2 Pfizer Inc. (US)
    • 19.2.1 Overview
    • 19.2.2 Recent Developments
    • 19.2.3 Financial Analysis
  • 19.3 GlaxoSmithKline plc (UK)
    • 19.3.1 Overview
    • 19.3.2 Recent Developments
    • 19.3.3 Financial Analysis
  • 19.4 Novartis AG (Switzerland)
    • 19.4.1 Overview
    • 19.4.2 Recent Developments
    • 19.4.3 Financial Analysis
  • 19.5 Bayer AG (Germany)
    • 19.5.1 Overview
    • 19.5.2 Recent Developments
    • 19.5.3 Financial Analysis
  • 19.6 Eli Lilly and Company (US)
    • 19.6.1 Overview
    • 19.6.2 Recent Developments
    • 19.6.3 Financial Analysis
  • 19.7 Merck & Co., Inc. (US)
    • 19.7.1 Overview
    • 19.7.2 Recent Developments
    • 19.7.3 Financial Analysis
  • 19.8 AstraZeneca
    • 19.8.1 Overview
    • 19.8.2 Recent Developments
    • 19.8.3 Financial Analysis

List of Figures

  • Figure-01: Global - Multiple Myeloma (MM) Market (Billion US$), 2017 - 2022
  • Figure-02: Global - Forecast for Multiple Myeloma (MM) Market (Billion US$), 2023 - 2030
  • Figure-03: Global - Multiple Myeloma (MM) Patient Population (Thousand), 2017 - 2022
  • Figure-04: Global - Forecast for Multiple Myeloma (MM) Patient Population (THousand), 2023 - 2030
  • Figure-05: Top 10 Countries - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-06: Top 10 Countries - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-07: United States - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-08: United States - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-09: Germany - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-10: Germany - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-11: France - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-12: France - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-13: United Kingdom - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-14: United Kingdom - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-15: Italy - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-16: Italy - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-17: Spain - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-18: Spain - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-19: Japan - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-20: Japan - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-21: Australia - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-22: Australia - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-23: China - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-24: China - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-25: Saudi Arabia - Epidemiology Scenario Patient Population (Number), 2017 - 2022
  • Figure-26: Saudi Arabia - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
  • Figure-27: Top 10 Countries - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-28: Top 10 Countries - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-29: Top 10 Countries - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-30: Top 10 Countries - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-31: United States - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-32: United States - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-33: United States - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-34: United States - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-35: Germany - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-36: Germany - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-37: Germany - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-38: Germany - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-39: France - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-40: France - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-41: France - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-42: France - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-43: United Kingdom - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-44: United Kingdom - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-45: United Kingdom - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-46: United Kingdom - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-47: Italy - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-48: Italy - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-49: Italy - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-50: Italy - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-51: Spain - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-52: Spain - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-53: Spain - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-54: Spain - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-55: Japan - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-56: Japan - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-57: Japan - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-58: Japan - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-59: Australia - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-60: Australia - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-61: Australia - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-62: Australia - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-63: China - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-64: China - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-65: China - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-66: China - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-67: Saudi Arabia - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
  • Figure-68: Saudi Arabia - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
  • Figure-69: Saudi Arabia - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
  • Figure-70: Saudi Arabia - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
  • Figure-71: Top 10 Countries - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-72: Top 10 Countries - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-73: United States - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-74: United States - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-75: Germany - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-76: Germany - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-77: France - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-78: France - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-79: United Kingdom - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-80: United Kingdom - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-81: Italy - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-82: Italy - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-83: Spain - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-84: Spain - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-85: Japan - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-86: Japan - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-87: Australia - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-88: Australia - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-89: China - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-90: China - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-91: Saudi Arabia - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-92: Saudi Arabia - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-93: Targeted Therapy - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-94: Targeted Therapy - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-95: Chemotherapy - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-96: Chemotherapy - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-97: Others - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
  • Figure-98: Others - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
  • Figure-99: Xpovio (Selinexor) - Karyopharm - Market (Million US$), 2018 - 2022
  • Figure-100: Xpovio (Selinexor) - Karyopharm - Forecast for Market (Million US$), 2023 - 2030
  • Figure-101: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical - Market (Million US$), 2018 - 2022
  • Figure-102: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical - Forecast for Market (Million US$), 2023 - 2030
  • Figure-103: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) - Market (Million US$), 2018 - 2022
  • Figure-104: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) - Forecast for Market (Million US$), 2023 - 2030
  • Figure-105: HDAC inhibitor (Farydak) - Novartis - Market (Million US$), 2018 - 2022
  • Figure-106: HDAC inhibitor (Farydak) - Novartis - Forecast for Market (Million US$), 2023 - 2030
  • Figure-107: Sarclisa (Isatuximab) - Sanofi - Market (Million US$), 2020 - 2022
  • Figure-108: Sarclisa (Isatuximab) - Sanofi - Forecast for Market (Million US$), 2023 - 2030
  • Figure-109: Sanofi - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-110: Sanofi - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-111: Pfizer Inc. - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-112: Pfizer Inc. - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-113: GlaxoSmithKline plc - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-114: GlaxoSmithKline plc - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-115: Novartis AG - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-116: Novartis AG - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-117: Bayer AG - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-118: Bayer AG - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-119: Eli Lilly and Company - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-120: Eli Lilly and Company - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-121: Merck & Co., Inc. - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-122: Merck & Co., Inc. - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
  • Figure-123: AstraZeneca - Global Revenue Market (Billion US$), 2018 - 2022
  • Figure-124: AstraZeneca - Forecast for Global Revenue Market (Billion US$), 2023 - 2030

List of Tables

  • Table-01: Global - Multiple Myeloma (MM) Market Share by Countries (Percent), 2018 - 2022
  • Table-02: Global - Forecast for Multiple Myeloma (MM) Market Share by Countries (Percent), 2023 - 2030
  • Table-03: Global - Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2018 - 2022
  • Table-04: Global - Forecast for Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2023 - 2030
  • Table-05: Global - Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2018 - 2022
  • Table-06: Global - Forecast for Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2023 - 2030
  • Table-07: Global - Multiple Myeloma (MM) Market Share by Gender (Percent), 2018 - 2022
  • Table-08: Global - Forecast for Multiple Myeloma (MM) Market Share by Gender (Percent), 2023 - 2030